SavedAdd your journal

Journals / European Journal of General Medicine / 2010 / Cilt: 7 Sayı: 4

Serum paraoxonase and arylesterase activities in esophageal cancer: a controlled study

Kerim Cayir
Mehmet Bilici
Salim Basol Tekin
Fatih Kara
Atilla Türkyilmaz
Abdülkadir Yildirim
Pages
398–403
Publication Date
2010-12-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗

Özet

-

🔖

Cite This Article

Cayir, K., Bilici, M., Tekin, S. B., Kara, F., Türkyilmaz, A., Yildirim, A. (2010). Serum paraoxonase and arylesterase activities in esophageal cancer: a controlled study. European Journal of General Medicine, Cilt: 7 Sayı: 4, 398–403. https://ajindex.com/articles/987752

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (25)

  1. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin 2007; 57:43-6.
  2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality and prevalence across five conti- nents: Defining priorities to reduce cancer disparities in different geographic response of the world. J Clin Oncol 2006; 24:2137-50.
  3. Day NE, Varghese C. Oesophageal cancer. Cancer Surv 1994; 19-20:43-54.
  4. Cejas P, Casado E, Belda-Iniesta C et al. Implications of oxidative stress and cell membrane lipid peroxida- tion in human cancer (Spain). Cancer Causes Control 2004;15:707-19.
  5. Behrend L, Henderson G, Zwacka RM. Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 2003; 31(Pt 6):1441–4.
  6. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329-36.
  7. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo- Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possi- ble peroxidative role for paraoxonase. J Clin Invest 1998; 101:1581–90.
  8. Li Hl, Liu DP, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 2003; 81:766-79.
  9. Schiavon R, Battaglia P, De Fanti E et al. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta 2002; 324:39-44.
  10. Akçay MN, Yilmaz I, Polat MF, Akçay G. Serum paraox- onase levels in gastric cancer. Hepatogastroenterology 2003; 50 (Suppl 2):cclxxiii-cclxxv.
  11. Akçay MN, Yilmaz I, Polat MF, Akçay G. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 2003; 50 (Suppl 2):ccxxv-ccxxvii.
  12. Elkiran ET, Mar N, Aygen B, Gursu F, Karaoglu A, Koca S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007;15:48.
  13. Furlong CE, Richter RJ, Seidel SL, Motulsky AG. Role of genetic polymorphism of human plasma paraoxonase/ arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 1988; 43:230-8.
  14. Eckerson HW, Wyte CM, La Du BN. The Human Serum Paraoxonase/Arylesterase Polymorphism. Am J Hum Genet 1983; 35:1126-38.
  15. Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in can- cer. Mutat Res 2001; 477:7-21.
  16. Demple B, Harrison L. Repair of oxidative damage to DNA: enzymology and biology. Annu Rev Biochem 1994; 63:915- 48.
  17. Cathcart MK, McNally AK, Chisolm GM. Lipoxygenase- mediated transformation of human low density lipopro- tein to oxidized and cytotoxic complex. J Lipid Res 1991; 32:63-70.
  18. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of teh human serum paraox- onase polymorphism is reserved with diazoxon and sarin. Nat Genet 1996; 14:334-6.
  19. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with in- creased macrophage oxidative stres: studies in PON1- knockout mice. Free Radic Biol Med 2003; 34:774-84.
  20. Kafadar AM, Ergen A, Zeybek U, Agachan B, Kuday C, Isbir T. Paraoxonase 192 gene polymorphism and serum para- oxonase activity in high grade gliomas and menegiomas. Cell Biochem Funct 2006; 24:455-60.
  21. Lee CH, Lee KY, Choe KH et al. Effects of oxidative DNA damage induced by polycylic aromatic hydrocarbons and genetic polymorphism of theparaoxonase -1 (PON1) gene on lung cancer. Prev Med Pub Health 2005; 38:345-50.
  22. Marchesani M, Hakkarainen A, Tuomainen TP et al. New paraoxonase 1 polymorphism II02V and the risk of pros- tate cancer in Finnish men. J Natl Cancer Inst 2003; 95:812-8.
  23. Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E. Association of CYP 17, GSTPI and PON1 polymorphisms with the risk of prostate cancer. Prostate 2005; 63:240- 51.
  24. Van Der Logt EM, Janssen CH, Van Hooijdonk Z et al. No association between genetic polymorphisms in NAD(P)H oxidase p22phox and paraoxonase 1 and colorectal cancer risk. Anticancer Res 2005; 25:1465-70.
  25. Eckerson HW, Wyte CM, La Du BN. The Human Serum Paraoxonase/Arylesterase Polymorphism. Am J Hum Genet 1983; 35:1126-38.